trending Market Intelligence /marketintelligence/en/news-insights/trending/9Vdc0MPPiABT8sdOBg5G6w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Clearside Biomedical's eye drug Xipere rejected by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Clearside Biomedical's eye drug Xipere rejected by US FDA

Clearside Biomedical Inc. said the U.S. Food and Drug Administration rejected its application for eye inflammation treatment Xipere.

The company was seeking approval to market Xipere as a treatment for macular edema associated with uveitis, a condition characterized by the buildup of fluid in a part of the eye —leading to vision loss and blindness.

It is estimated that uveitis affects about 350,000 patients in the U.S. and over one million globally; about one-third of patients develop uveitic macular edema.

In its complete response letter, the regulator asked for additional stability data on the new manufacturing process for Xipere, an injectable form of a synthetic corticosteroid called triamcinolone acetonide. Alpharetta, Ga.-based Clearside said it would be able to address the request, plus another for additional data on the clinical use of the delivery system for the medicine, and resubmit its application in the first quarter of 2020.

The company also said the FDA did not identify any efficacy issues and made no requests for further clinical efficacy studies, but did ask to reinspect the drug's product manufacturer.